Due to health issues, this site is no longer maintained and will be shut down shortly. |
StemoniX Inc. provides IPS-based platforms for pharma and research institutions. The company offers StemoniX, a platform that focuses on printing of stem-cell derived human tissue for custom drug discovery and personalized medicine. Its solution enables scaled 3-D printing of living cells into larger form factors for heart disease, dementia, breast cancer, autism, ALS, and more. The company was incorporated in 2014 and is headquartered in Minneapolis, Minnesota with an additional office in LA Jolla, California.
$0.65 -0.01 (-1.52%)
As of 03/24/2023 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.